Safety, Stability and Pharmacokinetic Properties of superFactor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding

Pharmaceutical Research

Volumn 33, Issue 6, 2016, Pages 1517-1526

  Gale, Andrew J ^a,e   Bhat, Vikas ^a   Pellequer, Jean Luc ^b,c   Griffin, John H ^a,d   Mosnier, Laurent O ^a   Von Drygalski, Annette ^a,d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^c CEA GRENOBLE   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Avelas Biosciences   (United States)

Author keywords

bleeding; factor V; hemophilia; hemostasis; immunogenicity; thrombogenicity

Indexed keywords

BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8; BUFFER; EPITOPE; FIBRIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPLASTIN; SODIUM CHLORIDE; THROMBIN; HEMOSTATIC AGENT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; B LYMPHOCYTE; BLEEDING DISORDER; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ANTIGENICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FEMALE; FIBRIN DEPOSITION; HEMOSTASIS; HUMAN; IMMUNOGENICITY; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PLASMA HALF LIFE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SURFACE AREA; T LYMPHOCYTE; THROMBOGENICITY; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; HALF LIFE TIME; HEMOPHILIA A; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; LUNG; METABOLISM; MUTATION; PROCEDURES; PROTEIN ENGINEERING; PROTEIN STABILITY; SEVERITY OF ILLNESS INDEX; SITE DIRECTED MUTAGENESIS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG STABILITY; FACTOR VA; FACTOR VIII; FEMALE; FIBRIN; HALF-LIFE; HEMOPHILIA A; HEMOSTATICS; HUMANS; INJECTIONS, INTRAVENOUS; LUNG; MALE; MICE, INBRED BALB C; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN ENGINEERING; PROTEIN STABILITY; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; THROMBIN;

EID: 84960106888     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1895-3     Document Type: Article

References (38)

1. Gale AJ, Xu X, Pellequer JL, Getzoff ED, Griffin JH. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci. 2002;11(9):2091–101.
2. von Drygalski A, Cramer TJ, Bhat V, Griffin JH, Gale AJ, Mosnier LO. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. J Thromb Haemost. 2014;12(3):363–72.
3. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem. 1988;57:915–56.
4. Schlachterman A, Schuettrumpf J, Liu JH, Freguia CF, Toso R, Poncz M, et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost. 2005;3(12):2730–7.
5. Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res. 2010;125(2):119–23.
6. Kalafatis M, Egan JO, Van’t Veer C, Cawthern KM, Mann KG. The regulation of clotting factors. Crit Rev Eukaryot Gene Expr. 1997;7(3):241–80.
7. Bos MH, Meijerman DW, Van der Zwaan C, Mertens K. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma? J Thromb Haemost. 2005;3(3):522–30.
8. Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem. 2004;279(20):21643–50.
9. Bhat V, von Drygalski A, Gale AJ, Griffin JH, Mosnier LO. Improved coagulation and hemostasis in hemophilia with inhibitors by combinations of superFactor Va and factor VIIa. Thromb Haemost. 2016;115(3):551–61.
10. Bhat V, Gale AJ, Griffin JH, Mosnier LO, von Drygalski A. Reversal of novel oral anticoagulant (NOAC)-induced bleeding in mice by engineered superFactor Va. Blood. 2014;124(21):695.
11. von Drygalski A, Bhat V, Gale AJ, Burnier L, Cramer TJ, Griffin JH, et al. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C. PLoS One. 2014;9(8):e104304.
12. Hoots WK. Arthropathy in inhibitor patients: differences in the joint status. Semin Hematol. 2008;45(2 Suppl 1):S42–9.
13. Astermark J, Donfield SM, Dimichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven comparative (FENOC) study. Blood. 2007;109(2):546–51.
14. Astermark J, Santagostino E, Keith HW. Clinical issues in inhibitors. Haemophilia. 2010;16 Suppl 5:54–60.
15. Howard BM, Daley AT, Cohen MJ. Prohemostatic interventions in trauma: resuscitation-associated Coagulopathy, acute traumatic Coagulopathy, hemostatic resuscitation, and other hemostatic interventions. Semin Thromb Hemost. 2012;38(3):250–8.
16. Levy JH, Spyropoulos AC, Samama CM, Douketis J. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv. 2014;7(12):1333–51.
17. Cramer TJ, Griffin JH, Gale AJ. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb. 2010;37(1):17–23.
18. Radtke KP, Griffin JH, Riceberg J, Gale AJ. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. J Thromb Haemost. 2007;5(1):102–8.
19. Mesters RM, Houghten RA, Griffin JH. Identification of a sequence of human activated protein C (residues 390–404) essential for its anticoagulant activity. J Biol Chem. 1991;266(36):24514–9.
20. Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4–15.
21. Hendrickx ML, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application. J Thromb Haemost. 2014;12(2):229–36.
22. Pellequer JL, Westhof E, Van Regenmortel MH. Correlation between the location of antigenic sites and the prediction of turns in proteins. Immunol Lett. 1993;36(1):83–99.
23. Odorico M, Pellequer JL. BEPITOPE: predicting the location of continuous epitopes and patterns in proteins. J Mol Recognit. 2003;16(1):20–2.
24. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2:2.
25. Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem. 2010;17(19):2059–69.
26. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinforma. 2007;8:424.
27. Chen SW, Pellequer JL. Adepth: new representation and its implications for atomic depths of macromolecules. Nucleic Acids Res. 2013;41:W412–6.
28. Gale AJ, Yegneswaran S, Xu X, Pellequer JL, Griffin JH. Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site. J Biol Chem. 2007;282(30):21848–55.
29. Rand MD, Hanson SR, Mann KG. Factor V turnover in a primate model. Blood. 1995;86(7):2616–23.
30. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102(10):3615–20.
31. Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270–9.
32. Elm T, Karpf DM, Ovlisen K, Pelzer H, Ezban M, Kjalke M, et al. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia. 2012;18(1):139–45.
33. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood. 2011;117(1):290–8.
34. Metzner HJ, Pipe SW, Weimer T, Schulte S. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost. 2013;110(5):931–9.
35. Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv. 2010;7(2):187–201.
36. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997–2006). Haemophilia. 2009;15(5):1027–31.
37. Kreuz W, Ettingshausen CE. Inhibitors in patients with haemophilia A. Thromb Res. 2014;134 Suppl 1:S22–6.
38. Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, et al. Changes in the amino acid sequence of the rFVIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015;13(11):1989–98.